BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202
Go back to BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 57.36 +0.03 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.33 | 52 Week High | $108.96 | |||
| Open | $57.46 | 52 Week Low | $62.12 | |||
| Day High | $57.95 | P/E | N/A | |||
| Day Low | $56.40 | EPS | $-1.27 | |||
| Volume | 941,139 | |||||
